Frustrating to see discussion (and/or tacit endorsement) of treatments unsupported by evidence at #ASCO24 . At the endometrial cancer session 40% of the audience voted to give trastuzumab deruxtecan to a patient with HER2 2+ IHC. This should be called out more strongly!